Halozyme Therapeutics HALO Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's debt-to-equity?
- Halozyme Therapeutics (HALO) reported debt-to-equity of 9.9× in Q1 2026.
- How has Halozyme Therapeutics's debt-to-equity changed year-over-year?
- Halozyme Therapeutics's debt-to-equity increased by 211.0% year-over-year, from 3.2× to 9.9×.
- What is the long-term trend for Halozyme Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's debt-to-equity has grown at a 75.7% compound annual growth rate (CAGR), from 2.7× to 44.6×.
- What does debt-to-equity mean?
- How much debt the company carries for every dollar of shareholder equity.
- How do you interpret debt-to-equity?
- Lower is generally safer, but moderate leverage can boost returns. Read in the context of cash-flow stability — a utility tolerates more debt than a cyclical. Negative equity makes the ratio meaningless and it is suppressed there.
- How does debt-to-equity compare across companies?
- Comparable within an industry; capital structures differ sharply across sectors. Not meaningful for banks.